Abstract. Autophagy has been reported to be involved in the occurrence and development of pancreatic cancer. However, the mechanism of autophagy-associated non-coding RNAs (ncRNAs) in pancreatic cancer remains largely unknown. In the present study, microarrays were used to detect differential expression of mRNAs, microRNAs (miRNAs), long ncRNAs (lncRNAs) and circular RNAs (circRNAs) post autophagy suppression by chloroquine diphosphate in PANC-1 cells. Collectively, 3,966 mRNAs, 3,184 lncRNAs and 9,420 circRNAs were differentially expressed. Additionally, only two miRNAs (hsa-miR-663a-5p and hsa-miR-154-3p) were underexpressed in the PANC-1 cells in the autophagy-suppression group. Furthermore, miR-663a-5p with 9 circRNAs, 8 lncRNAs and 46 genes could form a prospective ceRNA network associated with autophagy in pancreatic cancer cells. In addition, another ceRNA network containing miR-154-3p, 5 circRNAs, 2 lncRNAs and 11 genes was also constructed. The potential multiple ceRNA, miRNA and mRNA associations may serve pivotal roles in the autophagy of pancreatic cancer cells, which lays the theoretical foundation for subsequent investigations on pancreatic cancer.

Introduction

Pancreatic cancer is a highly aggressive and fatal malignancy, with stably high incidence and mortality for the past 30 years globally (1-4). Patients with pancreatic adenocarcinoma account for ~85% of all patients with pancreatic cancer and have a poor prognosis, compared with patients with other common solid tumors (2,5-9). Pancreatic cancer is primarily treated through surgical resection, whereas postoperative patients and patients with advanced disease are frequently subjected to adjuvant therapies with radiotherapy, chemotherapy, and a combination of radiotherapy and chemotherapy that are associated with high recurrence rates and poor treatment effectiveness (10). The recent development of and research into molecular targeted drugs have great significance for the early diagnosis and prognosis of malignant tumors, and have ushered a new era of tumor therapy (11 -15). However, the overall treatment effect of these drugs remains poor, and further investigation is required (16).

Autophagy is a process by which eukaryotic cells undergo self-degradation of intracellular damaged macromolecular proteins and organelles (17,18). Autophagy at the physiological level is necessary to maintain the stability of the internal environment, and the occurrence of a variety of diseases, including inflammation, tumors and degenerative diseases, is frequently accompanied by an abnormal autophagic level (19-25). Currently, well-characterized, autophagy-associated proteins include Beclin 1, microtubule-associated-protein-1-light-chain-3 (LC3) and P62, and well-studied pathways include mechanistic target of rapamycin (mTOR) and phosphoinositide 3-kinase (PI3K) pathways (26,27).

Recently, the important role of autophagy in tumors has been recognized (19,28). Studies demonstrated that pancreatic cancer cells have an increased autophagy level, compared with...
other tumor cells (29-34). The growth of PDAC had a distinct dependence on autophagy in vivo and in vitro (35). Inhibition of autophagy is effective for the treatment of pancreatic cancer through animal experiments (36). Another study revealed that autophagy can be activated by gemcitabine and ionizing radiation in the treatment of pancreatic cancer cells, and activated autophagy serves a role in cancer suppression (37). However, whether autophagy promotes the occurrence, development and prognosis of pancreatic cancer is controversial (38). Therefore, the role of autophagy in the occurrence, development, prognosis and treatment of pancreatic cancer and its mechanism requires further examination.

mRNA is a single-stranded RNA that is transcribed using one of the DNA chains as the template and carries the genetic information that guides protein synthesis. Thus, mRNA occupies an important position in the heredity dogma (39). mRNA serves a key role in various human diseases and is involved in autophagy pathways (40,41); for example, signal transducer and activator of transcription 3 could inhibit autophagy in pancreatic cancer cells (42) and ubiquitin specific peptidase 1 regulates autophagy by targeting Unc-51 like autophagy activating kinase 1 (ULK1) (43). Non-coding RNA (ncRNA) refers to RNA that does not encode a protein and includes ribosomal RNA (rRNA), transfer RNA (tRNA), small nuclear RNA (snRNA), long ncRNA (lncRNA), microRNA (miRNA) and circular RNA (circRNA) (44-50). The involvement of lncRNAs and miRNAs in cancer has been studied intensively, whereas the potential significance of circRNAs in tumors has attracted attention over the last two years (51). The post-transcriptional levels of circRNAs serve a notable regulatory role in gene expression (52). Furthermore, the sponge effect of circRNAs on miRNAs is an important mechanism (53). circRNAs can contain multiple miRNA binding sites, and attract miRNAs effectively to reduce miRNA-mediated mRNA inhibition (54-56). Based on the interaction between these three types of ncRNAs and the current research status in pancreatic cancer, it was considered that an investigation of the effect of IncRNAs and circRNAs as competitive endogenous RNAs (ceRNAs) on the targeting of miRNAs in the development of pancreatic cancer is beneficial.

Recently, the number of autophagy-associated IncRNAs has been determined to be limited (57-60), and investigations on circRNAs and their associations with autophagy have not been reported to date. However, due to autophagy being involved in the occurrence and development of a variety of diseases, including breast (61,62), gastric (63) and lung cancer (64), in the present study, the human pancreatic cancer cell line PANC-1 and gene chip technology was used to detect differential expression of mRNAs, miRNAs, IncRNAs and circRNAs under different autophagy levels, and to investigate the genes associated with autophagy in pancreatic cancer and their underlying molecular mechanisms.

Materials and methods

Cell treatment. The human pancreatic cancer cell line PANC-1 was obtained from the Cell Laboratory of Chinese Academy of Sciences (Shanghai, China) and cultured in complete Dulbecco's modified Eagle's medium (DMEM; Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) at 37°C. Due to chloroquine diphosphate being frequently used as a classic autophagic inhibitor (65,66), the following concentration gradient of chloroquine diphosphate (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) was designed as recommended by the manufacturer's protocols: 0, 25, 50, 75 and 100 µM. When the number of cells in the culture bottle grew to ~5x10^6 the original medium was replaced by a complete DMEM containing chloroquine diphosphate. Following treating the cells for 12 h at 37°C with the drug, the cellular proteins were immediately extracted using Radioimmunoprecipitation Assay Lysis Buffer (Beyotime Institute of Biotechnology, Haimen, China).

Western blotting. The lysis solution (radioimmunoprecipitation assay buffer: phenylmethylsulfonyl fluoride; 100:1; Beyotime Institute of Biotechnology) was prepared. The protein concentration in the lysate was determined with a bicinchoninic acid kit (Beyotime Institute of Biotechnology), according to the manufacturer's instructions. Western blotting was performed according to routine procedures, and conducted with a 12% separating gel and a 5% stacking gel. A total of 20 µg protein was added to the glue holes. The electrophoresis condition was set to 120 Ma for 1 h. Following the electrophoresis, the protein was transferred to the polyvinylidene (PVDF) membrane (Beyotime Institute of Biotechnology). Subsequently, the PVDF membrane was placed into the Bull Serum Albumin blocking buffer (Beyotime Institute of Biotechnology) for shaking at 37°C for 2 h. Primary antibodies were incubated at 4°C overnight and secondary antibodies were incubated at room temperature for 2 h. The primary antibodies were LC3 β-specific rabbit polyclonal (1:1,000; cat. no. 18725-1-AP) and P62 mouse monoclonal antibodies (1:2,000; cat. no. 66184-1-Ig), which represented the state of autophagy, and the GAPDH monoclonal antibodies (1:1,000; cat. no. SA00002-1) (all from ProteinTech Group, Inc., Chicago, IL, USA). The gray scale values of the protein bands from the raw image were determined using the ImageJ 1.48 (National Institutes of Health, Bethesda, MD, USA) and the formula Final gray scale value (G) = [G x (target band)] / [G x (internal reference band of the group)] - G x (background)]. The data were analyzed using SPSS software 22 (SPSS, Inc., Chicago, IL, USA), and the results were plotted using the GraphPad Prism 5 software (GraphPad Software, Inc., La Jolla, CA, USA).

Sample grouping. Based on the results of the western blotting experiment, the human pancreatic cancer PANC-1 cells treated with 100 µM chloroquine diphosphate were selected as the autophagic inhibition group, and the cells cultured in normal DMEM medium were selected as the control group. Subsequent experiments were compared between the autophagic inhibition group and the control group. Following chloroquine diphosphate treatment, total RNA was prepared using the TRIzol® reagent (Beyotime Institute of Biotechnology) with three replicates per group.

cerNA microarray and detection, and statistical analysis of the miRNA chip results. The quality control for the gene
analyses in the present study was performed by Shanghai Biotechnology Corporation (Shanghai, China). The starting sample of the microarray test was total RNA, which was analyzed with the NanoDrop ND-2000 spectrophotometer and the Agilent Bioanalyzer 2100 (Agilent Technologies, Inc., Santa Clara, CA, USA) to conduct the quality control assay. Only RNA samples that passed the quality control procedure proceeded to the subsequent microarray experiments. The qualifying sample standards were that the RNA integrity number of each sample was ≥7.0 and that the 28S/18S was ≥0.7.

The ceRNA microarray detection assay included the detection of three types of RNA (lncRNA, circRNA and mRNA). The cutoff values of the differentials were all set to a fold change (FC) > 2 or FC < 0.5 and P < 0.05. The assays and data analyses are described below. The analyses primarily included the normalization of raw data, sample association analysis, screening of genes with differential expression, Gene Ontology (GO) enrichment analysis of the differentially-expressed mRNAs, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis, PANTHER pathway analysis of the differentially-expressed mRNAs, prediction of lncRNA and circRNA target genes, and prediction of lncRNA and circRNA adsorption of miRNAs. GO and KEGG pathway enrichment analysis was performed using the WebGestalt 2017 tool (http://www.webgestalt.org) while PANTHER was analyzed using the WebGestalt 2017 tool (http://www.webgestalt.org/option.php). The clinical roles of genes were analyzed through the online database of Gene Expression Profiling Interactive Analysis (GEPIA; http://gepia.cancer-pku.cn/) which is based on the data obtained from The Cancer Genome Atlas and GTEx. The miRNA microarray analyses primarily included the normalization of raw data, sample association analysis, screening of differentially-expressed miRNAs and prediction of miRNA target genes, which was predicted by 12 online databases [DIANA-microTv4.0 (67), DIANA-microT-CDS (68), miRanda-rel2010 (69), mirbridge (70), miRDB4.0 (71), miRMap (72), miRNAMap (73), PicTar2 (74), PITA (75), RNA22v2 (76), RNAhybrid2.1 (77) and Targetscan6.2 (78)] (http://zmf.umm.uni-heidelberg.de/apps/zmf/mirwalk2/). The crossed genes from target prediction and differentially-expressed mRNAs were depicted in Compendia expression profiles (Novartis; http://software.broadinstitute.org/gsea/msigdb/annotate.jsp).

Network visualization was performed in Cytoscape 3.5.1 (The Cytoscape Consortium, New York, NY, USA).

The raw data of ceRNA microarray has been deposited in the Gene Expression Omnibus (GEO) database (https://www.ncbi.nlm.nih.gov/geo/) with accession number GSE115517.

**Tissue samples.** A total of 31 formalin-fixed paraffin-embedded (FFPE) tissues, including 18 cases of Pancreatic ductal adenocarcinoma and 13 paracancerous tissues, were collected from the Department of Pathology of the First Affiliated Hospital of Guangxi Medical University (Nanning, China) between June 2015 and June 2018. The present study was approved by the Ethics Committee of the First Affiliated Hospital of Guangxi Medical University. All cases were from patients who have not been treated with chemotherapy or radiation prior to resection and have signed informed consent. There were 11 male and 7 female aged 29-77 years (mean age, 56 years) in 18 patients with adenocarcinoma.

**RNA extraction and Real-time fluorescent quantitative PCR (RT-qPCR).** According to the user guide provided by the manufacturer, the total RNA of tissues was extracted using an E.Z.N.A.® FFPE RNA kit (Omega Bio-Tek, Inc., Norcross, GA, USA). The complementary DNA (cDNA) was reverse transcribed through the kit of miRNA First Strand cDNA Synthesis [Tailing Reaction (79,80)] (Sangon Biotech Co., Ltd., Shanghai, China), and RT-qPCR was conducted by applying a MicroRNAs qPCR kit [SYBR® Green method (81,82)] (Sangon Biotech Co., Ltd.), according to the manufacturer’s protocols, on an ABI Prism 7500 (Applied Biosystems; Thermo Fisher Scientific, Inc.). The temperature of pre-denaturation and denaturation were both set at 95°C, and the temperature of annealing/extension was set at 60°C. Pre-denaturation was conducted for 10min, denaturation for 15 sec and annealing/extension for 60 sec. The number of cycles was set to 40. Subsequently, the expression of miRNA relative to U6 was calculated via the 2[-ΔΔCq] method on identical samples (83). The PCR primers included: i) miR-663a-5p forward, 5'-ATAGCGGGGGCCCGGGCAC-3'; ii) miR-154-3p forward, 5'-CCGGGAATCTAGACCGTGTGAGCGT-3'; and iii) U6 forward and universal PCR reverse primer were attached to the kits. Their primer sequences are

![CeRNA network of miR-663a-5p and miR-154-3p](image-url)
5′-CTCGCTTCGGCAGCACA-3′ and 5′-AACGCTTCACGATTTGCGT-3′, respectively.

*Retrieval of data from GEO.* Within GEO, ‘pancreas’ or ‘pancreatic’, and ‘adenocarcinoma’, ‘carcinoma’, ‘cancer’, ‘neoplasm’, ‘tumor’, ‘tumour’, ‘neoplas*’ malig*’ , ‘PDAC’, ‘OR’, ‘PAAD’ or ‘PC’ were employed as a search strategy in GEO to determine the expression of miR-663a-5p and miR-154-3p. STATA 12.0 (StataCorp LLC, College Station, TX, USA) was applied to estimate the pooled effects, heterogeneity and publication bias.

*Statistical analysis.* The data of GEO and RT-qPCR were calculated using SPSS 22 software for mean and standard deviation (SD). Continuous data are presented as mean ± SD. The forest plots were produced by Stata 12.0. The heterogeneity test was used to analyze the existence of heterogeneity and the source of the occurrence of heterogeneity (I^2 >50% or P<0.05 is the existence of heterogeneity). Funnel plots were used for the analysis of publication bias. The comparison between the two groups was performed using two-sample Student’s t-test. The method for differential gene expression analysis in GEPIA was one-way analysis of variance, using pathological stage as variable for calculating differential expression. GEPIA performs overall survival analysis based on gene expression. GO analysis was performed in DAVID tool which used Fisher’s exact test and the techniques of Kappa statistics (84). PANTHER analysis was performed in WebGestalt, which used Hypergeometric and Fisher’s exact tests. P<0.05 was considered to indicate a statistically significant difference.

**Results**

*Autophagy following chloroquine diphosphate treatment.* The present study design of the whole investigation is depicted in Fig. 1. The LC3-II expression level was significantly reduced in the control group, compared with the group treated with 25 or 100 µM chloroquine diphosphate (P<0.05). However, the P62 expression level was significantly increased in the group treated with 100 µM chloroquine diphosphate, compared with the control group or the groups treated with 25, 50, 75 or 100 µM chloroquine diphosphate (P<0.05). Thus, the 100 µM concentration of chloroquine diphosphate had the greatest significant inhibitory effect on autophagy in human pancreatic cancer PANC-1 cells (Fig. 2).

*Quality control of samples for the ceRNA microarray and miRNA microarray chips.* Electrophoresis of the RNA samples indicated that the RNA integrity number of each sample was ≥7.0 and that the 28S/18S was ≥0.7, which reached the qualifying sample standards. Thus, the samples were qualified for use in the subsequent experiments.

*Assays to identify differentially-expressed mRNAs, lncRNAs, circRNAs and miRNAs.* The ceRNA microarray results determined 3,966 differentially-expressed mRNAs in total. The expression levels of 2,445 mRNAs in the PANC-1 cells from the chloroquine diphosphate treatment group (autophagy suppression group) were downregulated and 1,521 mRNAs were upregulated, compared with the control group (Fig. 3). Additionally, 3,184 differentially-expressed lncRNAs were
observed, including 1,637 downregulated and 1,547 upregulated (Fig. 4), whereas 9,420 circRNAs were determined to be differentially expressed, including 4,223 downregulated and 5,197 upregulated (Fig. 5). The miRNA microarray results demonstrated that the expression levels of two miRNAs (hsa-miR-663a-5p and hsa-miR-154-3p) were underexpressed in the PANC-1 cells in the autophagy-suppression group, compared with the control group. No upregulated miRNA was determined. The cutoff values of the aforementioned differentials were all set to a fold change>2 or FC<0.5 and P<0.05.

Bioinformatics analysis of the functions of the differentially-expressed mRNAs. GO and KEGG pathway analyses were performed using the DAVID database. The 3,966 differentially-expressed mRNAs in the chloroquine diphosphate treatment group (autophagy suppression group), compared with the control group, were subjected to bioinformatics analysis of their functions. The results demonstrated that these genes were concentrated in the biological processes, molecular functions and cellular components categories in the GO analysis (Table I), and were involved in the regulation of multiple KEGG signaling pathways including pathways in cancer and the mitogen-activated protein kinase signaling pathway (Table II). Of these functions, the involvement of the autophagy-associated pathway (Autophagy) was notable. Additionally, the differentially-expressed genes in this pathway included a number of recognized autophagy-associated genes, including autophagy-related 12 (ATG12), GABA type A receptor associated protein like 1 (GABARAPL1) and ULK2, which were differentially expressed in the present ceRNA microarray results also (Fig. 6). Following analyzing the clinical roles of the three genes via the Gene Expression Profiling Interactive Analysis online database, which is based on the data obtained from The Cancer Genome Atlas and GTEx, it was determined that the expression of ATG12 was upregulated in pancreatic cancer tissue, compared with non-tumor tissue. Furthermore, high expression of ATG12 was associated with significantly reduced survival time (P<0.01). Notably, the expression of ATG12, GABARAPL1 and ULK2 were increased in pancreatic cancer, compared with the control group (Fig. 6). These results validated that these autophagy-associated genes were involved in the onset and progression of pancreatic cancer.

Prediction of target genes of the differentially-expressed miRNAs and the bioinformatics analysis of their functions. These results were integrated with the differentially-expressed mRNAs that were actually measured. The co-expressed genes were subjected to GO and KEGG pathway analyses using the DAVID database. Prediction of miR-663a-5p target genes and bioinformatics analysis of their functions. A total of 1,726 target genes of miR-663a-5p were detected by at least 6 platforms using the aforementioned 12 online miRNA target gene prediction databases. Following cross-checking with the differentially-expressed genes in the autophagy suppression group derived from chloroquine diphosphate treatment, 462 co-expressed genes were obtained (Fig. 7). These genes were subjected to GO and KEGG pathway analyses. The results demonstrated that these genes were concentrated in the biological processes, molecular functions and cellular components categories in the GO analysis (Fig. 8A, Table III) and were involved in the regulation of multiple KEGG signaling pathways (Table III), including the aldosterone-regulated sodium reabsorption and Wnt signaling pathways (Fig. 8B-D). However, there were no significant pathways determined by PANTHER analysis (P>0.05).

Prediction of miR-154-3p target genes and bioinformatics analysis of their functions. A total of 294 target genes of miR-154-3p were detected by at least 6 programs using the aforementioned 12 online miRNA target gene
Following cross-checking with the differentially-expressed genes in the autophagy suppression group derived from chloroquine diphosphate treatment, 294 co-expressed genes were obtained (Fig. 9). These genes were subjected to GO and KEGG pathway analyses. The results demonstrated that these genes were concentrated in prediction databases.
the biological processes, molecular functions and cellular components categories in the GO analysis (Fig. 10A, Table IV), and were involved in the insulin signaling, Forkhead Box O (FoxO) signaling and proteoglycans in cancer pathways (Table IV, Fig. 10B-D). Additionally, the results of PANTHER analysis revealed these genes were concentrated in a numbered of pathways, including the p53 pathway by glucose deprivation and the classical gastrin cholecystokinin receptor (CCKR) signaling map (Table V, Fig. 11).

**Prediction of ceRNAs of the differentially-expressed miRNAs.**

Different online platforms were used to predict the target genes of the differentially-expressed miRNAs. The target circRNAs and lncRNAs of the differentially-expressed miRNAs were searched based on the prediction of the target miRNAs of the differentially-expressed circRNAs and lncRNAs revealed by microarray detection, and the differentially-expressed miRNAs that were detected. The ceRNAs that were negatively associated with the expression of the miRNAs were selected.

**Prediction of ceRNAs of miR-663a-5p.**

A total of 21 differentially-expressed circRNAs that targeted miR-663a-5p were determined, of which nine (hsa_circ_0003176, hsa_circ_0048579, hsa_circ_0063706, hsa_circ_0071922, hsa_circ_0078989, hsa_circ_0079319, hsa_circ_0083080, hsa_circ_0089643 and hsa_circ_0090372) indicated negative associations with miR-663a-5p expression. hsa_circ_0071922 had the highest number of binding sites for miR-663a-5p, with six. Simultaneously, 45 differentially-expressed lncRNAs that targeted miR-663a-5p were determined, of which 8 lncRNAs (RP11-59C5.3, RP13-516M14.8, RP11-196G18.24, AJ006995.3, AC024560.2, PPPIR1C, LINC00595 and HAGLROS) were negatively associated with miR-663a-5p expression. All of these lncRNAs had one miR-663a-5p binding site (Table VI). Subsequently, 144 common predicted targets from at least 8 among 12 programs were collected, and then they were intersected into the 3,966 differentially-expressed genes following autophagy inhibition. Collectively, 46 potential targets were determined. Thus, a ceRNA hypothesis figure with miR-663a-5p, 9 circRNAs, 8 lncRNAs and 46 genes was depicted in Fig. 12.

**Prediction of ceRNAs of miR-154-3p.**

A total of 6 differentially-expressed circRNAs that targeted miR-154-3p were determined, of which five (hsa_circ_0000156, hsa_circ_0004089, hsa_circ_0006461, hsa_circ_0015157 and hsa_circ_0038665) indicated a negative association with miR-154-3p expression. All of these circRNAs had two miR-154-3p binding sites. Simultaneously, 16 differentially-expressed lncRNAs that targeted miR-154-3p were determined, of which two (RP11-686O6.1 and LINC01140) were negatively associated with miR-154-3p expression. These lncRNAs had one miR-154-3p binding site (Table VI). Similarly to miR-663a-5p, 67 common predicted targets of miR-154-3p from at least 8 among 12 platforms were collected, and then they were intersected into the 3,966 differentially-expressed genes following autophagy suppression. Eventually, 11 potential targets were collected. Hence, a ceRNA hypothesis network with miR-154-3p, 5 circRNAs, 2 lncRNAs and 11 genes was presented (Fig. 13).

**Meta-analysis of miR-663a-5p and miR-154-3p expression based on RT-qPCR and GEO data.** A comprehensive analysis.

---

**Table II. Kyoto Encyclopedia of Genes and Genomes pathway analysis of differentially-expressed mRNAs when autophagy was inhibited.**

| Pathway ID | Description | Genes |
|------------|-------------|-------|
| hsa05200   | Pathways in cancer | BCR, PDGFB, WNT4, ETS1, CASP8, BRCA2, ARHGEF11, TRAF3, GNAI3 and BID |
| hsa04600   | Cytokine-cytokine receptor interaction | CCL4, PDGFB, IL4R, CCL21, IL12A, CSF2, GH2, CCL27, ACVR1B and LEP |
| hsa04100   | MAPK signaling pathway | PDGFB, MAP2K6, CACNG8, RPS6KA2, PLA2G4A, MAP3K4, GADD45G, CACNB3, JUN and TNFRSF1A |
| hsa04144   | Endocytosis | FOLR3, NEDD4L, PSD4, SH3KBP1, GRK5, ERBB4, EHD2, CAV2, ITCH and EPS15L1 |
| hsa04080   | Neuroactive ligand-receptor interaction | ADRA1D, GH2, PTAFR, C5AR1, GRN3B, HTR1B, LEP, S1PR5, LPAR2, CHRND, AGTR1, GH1, CHRM1, SSTR5, ADRA1B, GRIN3A, DRD5 and PTGER3 |
| hsa04621   | NOD-like receptor signaling pathway | CASP8, ATG12, TRAF3, TRAF5, JUN, OAS3, OAS1, MAVS, RNASEL and NLRP7 |
| hsa00230   | Purine metabolism | PFAS, PDE6G, POLD3, NME7, PDE9A, POLR3H, POLR2L, ADCY7, NME6 and NPR2 |
| hsa04110   | Cell cycle | RAD21, CDC16, E2F2, SFN, GADD45G, CCNH, CDC20, CDC25A, CCNA1 and TP53 |
| hsa04062   | Chemokine signaling pathway | CCL4, CCL21, GNAI3, PIK3R5, GRK5, CCL27, PIK3CB, SHC1, VAV1 and CCL4L1 |
| hsa04210   | Apoptosis | CASP8, BID, PIK3R5, CTSC, LMNB1, PIK3CB, EIF2AK3, GADD45G, CASP6 and TRADD |

Only 10 genes were listed as examples in each pathway. MAPK, mitogen-activated protein kinase.
WEI et al: ceRNA NETWORKS IN AUTOPHAGY SUPPRESSION OF PANCREATIC CANCER

Figure 6. Expression level, stage and overall survival curves of ATG12, GABARAPL1 and ULK2 in patients with pancreatic cancer. (A) The fold change of ATG12 (fold change=2.34), GABARAPL1 (fold change=3.90) and ULK2 (fold change=2.29) in the chloroquine diphosphate treatment group, compared with the control group. (B) The expression of ATG12 was upregulated in pancreatic cancer tissues, compared with normal tissues [T, n=179; N, n=171]. (C) ATG12 expression in different stages of pancreatic cancer is not significantly different (P=0.6140). (D) Patients with pancreatic cancer and a low expression of ATG12 have an increased survival time, compared with those with a high expression of ATG12 (HR=1.8; P=0.0042). (E) GABARAPL1 has an increased expression in pancreatic cancer tissues, compared with normal tissues [T, n=179; N, n=171]. (F) The association between GABARAPL1 and stage of patients with pancreatic cancer (P=0.5940). (G) The effect of GABARAPL1 expression on the overall survival time of patients with pancreatic cancer is not significant (HR=0.72; P=0.1100). (H) ULK2 has an increased expression in pancreatic cancer tissues, compared with normal tissues [T, n=179; N, n=171]. (I) The association between ULK2 and stage of patients with pancreatic cancer (P=0.0248). (J) The effect of ULK2 expression on the overall survival time of patients with pancreatic cancer is not significant (HR=0.79; P=0.2500). ATG12, autophagy-related 12; GABARAPL1, GABA type A receptor associated protein like 1; ULK2, Unc-51 like autophagy activating kinase 2; HR, hazard ratio; TPM, transcript per million.
Figure 7. Potential target genes of microRNA-663a-5p associated with autophagy. The 462 genes from target prediction and differentially-expressed mRNAs were depicted in Compendia expression profiles.
for the expression of miR-663a-5p and miR-154-3p in pancreatic cancer tissues was performed based on RT-qPCR and GEO data. The combined standardized mean difference (SMD) values of miR-663a-5p was -0.203 [95% confidence interval (CI), -0.675-0.269; Fig. 14A], which indicated that miR-663a had low expression in pancreatic cancer tissues;
Table III. GO and KEGG analysis of potential target genes of microRNA-663a-5p related to autophagy.

| Term | Description | Type | Count | P-value | Genes |
|------|-------------|------|-------|---------|-------|
| GO:0048562 | Embryonic organ morphogenesis | Biological process | 11 | 1.66x10^-3 | DLX2, FOXL2, TBX15, MAFB, CHST11, NKKX-2, SOBP, TBX1, ZEB1 and PAX2 |
| GO:0045449 | Regulation of transcription | Biological process | 87 | 1.71x10^-3 | ZNF451, NR6A1, ZNF250, CBX2, ZEB1, MED22, PAX2, CBFA2T3, ZNF345 and TGFβ1 |
| GO:0006350 | Transcription | Biological process | 73 | 1.78x10^-3 | NR6A1, ZNF451, ZNF250, CBX2, MED22, ZEB1, PAX2, CBFA2T3, ZNF345 and CRX |
| GO:0043583 | Ear development | Biological process | 9 | 2.35x10^-3 | KCNMA1, MAFB, NKKX-2, SOBP, TBX1, PAX2, SLC9A3R2, TGFβ1 and CDH23 |
| GO:0017015 | Regulation of transforming growth factor β receptor signaling pathway | Biological process | 6 | 2.54x10^-3 | DAND5, CHST11, TGFβ1I1, ZEB1, PRDM16 and TGFβ1 |
| GO:0048839 | Inner ear development | Biological process | 8 | 3.27x10^-3 | KCNMA1, MAFB, SOBP, TBX1, PAX2, SLC9A3R2, TGFβ1 and CDH23 |
| GO:0048568 | Embryonic organ development | Biological process | 12 | 3.56x10^-3 | DLX2, FOXL2, TBX15, MAFB, FOXF1, CHST11, NKKX-2, SOBP, TBX1 and ZEB1 |
| GO:0006357 | Regulation of transcription from RNA polymerase II promoter | Biological process | 31 | 3.82x10^-3 | TADA3, CRTC1, NR6A1, CBX2, ZEB1, MED22, PAX2, PRDM16, ZNF345 and TGFβ1 |
| GO:0006355 | Regulation of transcription DNA-dependent | Biological process | 62 | 3.88x10^-3 | NR6A1, ZNF250, CBX2, MED22, ZEB1, CBFA2T3, PAX2, ZNF345, TGFβ1 and CRX |
| GO:0048598 | Embryonic morphogenesis | Biological process | 17 | 3.96x10^-3 | FOXL2, TBX15, MAFB, ARFRP1, TP53, SOBP, TBX1, ZEB1, CELSR1 and PAX2 |
| GO:0030054 | Cell junction | Cellular component | 27 | 1.02x10^-4 | ACHE, CLDN9, PANX2, CLDN6, GRIK5, ZNRF1, ITSN1, SYNGR1, CALB2 and RIMS3 |
| GO:0045202 | Synapse | Cellular component | 21 | 1.45x10^-4 | KCNMA1, DLGAP1, ACHE, CDK5R1, ARC, EFNA2, SYT11, GRIK5, BCAN and BSN |
| GO:0044459 | Plasma membrane part | Cellular component | 68 | 4.22x10^-3 | KCN1, PCDHA8, CLDN9, CD8A, CLDN6, GRIK5, ANPEP, SYNGR1, ITSN1 and ZNRF1 |
| GO:0019717 | Synaptosome | Cellular component | 7 | 1.19x10^-2 | PVRL1, SNPH, DLG4, BSN, LGI3, ITSN1 and RNF40 |
| GO:0030173 | Integral to golgi membrane | Cellular component | 5 | 1.53x10^-2 | ST6GAL1, ST6SIA4, RER1, STEAP2 and ABO |
| GO:0031228 | Intrisin to golgi membrane | Cellular component | 5 | 1.92x10^-2 | ST6GAL1, ST6SIA4, RER1, STEAP2 and ABO |
| GO:0005794 | Golgi apparatus | Cellular component | 29 | 3.41x10^-2 | SLC9A8, ACHE, APC2, C6ORF25, PPL2, ARFRP1, RER1, VPS53, CBFA2T3 and NUFP2 |
| GO:0005886 | Plasma membrane | Cellular component | 99 | 4.57x10^-2 | KCN1, ALPPL2, PLXNA1, ATP1B2, C6ORF25, EFNA2, FGFR1L, GRIK5, ZNRF1, TLR6 and ITSN1 |
| GO:0031012 | Extracellular matrix | Cellular component | 14 | 4.66x10^-2 | ACHE, ADAMTS14, ADAMTS12, ADAMTS15, OLFML2A, BCAN, COL5A1, MMP25, TGFβ1 and WNT7B |
Table III. Continued.

| Term                  | Description                        | Type                  | Count | P-value     | Genes                                                                 |
|-----------------------|------------------------------------|-----------------------|-------|-------------|----------------------------------------------------------------------|
| GO:0005667            | Transcription factor complex        | Cellular component    | 10    | 4.72x10^-2 | BRF1, TADA3, TBX2, MAFB, FOXF1, NR6A1, TP53, NPAS4, ZEB1 and CRX      |
| GO:0046872            | Metal ion binding                  | Molecular function    | 123   | 1.21x10^-2 | KCNC1, SLC9A8, ALAD, FSTL4, ALPPL2, ATP1B2, ZNF451, ZNF250, RNF216 and ITSN1 |
| GO:0008270            | Zinc ion binding                   | Molecular function    | 74    | 1.44x10^-2 | ALPPL2, ALAD, ZCCHC24, ZNF451, NR6A1, SOBP, ZNF250, ANPEP, RNF216 and ZEB1 |
| GO:0043169            | Cation binding                     | Molecular function    | 123   | 1.64x10^-2 | KCNC1, SLC9A8, ALAD, ALPPL2, ATP1B2, ZNF451, FSTL4, ZNF250, RNF216 and ITSN1 |
| GO:003677             | DNA binding                        | Molecular function    | 72    | 3.34x10^-2 | PRR12, NR6A1, ZNF451, ZNF250, CBX2, ZEB1, PXA2, CBFA2T3, ZNF345 and CRX |
| GO:0046914            | Transition metal ion binding       | Molecular function    | 84    | 3.45x10^-2 | KCNC1, SLC9A8, ALAD, ALPPL2, ATP1B2, ZNF451, FSTL4, ZNF250, RNF216 and ITSN1 |
| GO:0030955            | Potassium ion binding              | Molecular function    | 8     | 4.02x10^-2 | KCNC1, SLC12A7, PKD1, ATP1B2, KCNK5, HCN4 and KCNG1                   |
| GO:0030528            | Transcription regulator activity    | Molecular function    | 49    | 4.27x10^-2 | NR6A1, CBX2, ZEB1, MED22, CBFA2T3, ZNF345, TGFB1, CRX, FOXF1 and ZNF445 |
| GO:0016419            | S-malonyltransferase activity      | Molecular function    | 2     | 4.90x10^-2 | MCAT and FASN                                                          |
| hsa04960              | Aldosterone-regulated sodium reabsorption | KEGG pathway       | 5    | 9.51x10^-3 | ATP1B2, PIK3R5, NEDD4L, SFN and SLC9A3R2                              |
| hsa04310              | Wnt signaling pathway              | KEGG pathway         | 8    | 2.92x10^-2 | WNT7B, SOST, VANGL1, APC2, TP53, FZD1, FRA1 and FZD4                  |
| hsa05217              | Basal cell carcinoma               | KEGG pathway         | 5    | 3.03x10^-2 | WNT7B, APC2, TP53, FZD1 and FZD4                                     |
| hsa00061              | Fatty acid biosynthesis            | KEGG pathway         | 3    | 3.08x10^-2 | MCAT, FASN and ACSL6                                                  |
| hsa04151              | PI3K-Akt signaling pathway         | KEGG pathway         | 14   | 3.48x10^-2 | FGF18, IL2RB, LAMB3, FLT1, IL4R, CSF1, EFNA2, TP53, TNN and EFNA5     |
| hsa05205              | Proteoglycans in cancer            | KEGG pathway         | 9    | 6.69Ex10^-2 | WNT7B, CTTN, EZR, ANK1, TP53, FZD1, PIK3R5, FZD4 and TGFBI3           |
| hsa04724              | Glutamatergic synapse              | KEGG pathway         | 6    | 9.94x10^-2 | DLGAP1, SLC1A7, DLG4, GRK5, CACNA1D and SHANK3                        |

Only 10 genes were listed as examples in each pathway. GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; PI3K, phosphoinositide 3-kinase.

however, heterogeneity existed ($I^2=63.6\%; P=0.011$; Fig. 14B). Sensitivity analysis and publication bias of miR-663a-5p were depicted in Fig. 14C. The combined SMD values of miR-154-3p was -0.434 (95% CI, -1.079-0.212; Fig. 15A)], which indicated that miR-154-3p had low expression in pancreatic cancer tissues; however, heterogeneity existed ($I^2=76.0\%; P=0.001$; Fig. 15B). Sensitivity analysis and publication bias of miR-154-3p were depicted in Fig. 15C.
Pancreatic cancer is one of the common malignancy types of the digestive system. Due to the lack of an effective early diagnosis, numerous patients are already in the advanced stage of the cancer when diagnosed (85). Currently, pancreatic cancer treatment remains dominated by surgical resection, which has a low five-year survival rate (86-88). Therefore, there is an urgent requirement for a series of effective markers for pancreatic cancer to change the current status of the...
poor efficacy of individualized treatment. Recent studies demonstrated that although ncRNAs do not encode proteins, they serve a pivotal role in the regulation of a variety of malignant tumor types, including gastric (89), pancreatic (90), prostate (91) and breast cancer (92). Over the past two years, the extensively investigated ncRNAs, including lncRNAs and...
Table IV. GO and KEGG analysis of potential target genes of microRNA-154-3p associated with autophagy.

| Term                  | Description                                                                 | Type                          | Count | P value     | Genes                                                                 |
|-----------------------|-----------------------------------------------------------------------------|-------------------------------|-------|-------------|------------------------------------------------------------------------|
| GO:0007605            | Sensory perception of sound                                                 | Biological process            | 11    | 1.67x10^-3 | NAV2, ASIC2, DCDC2, SOBP, TBX1, TIMM13, CACNA1D, FZD4, SLC52A3 and DNMI |
| GO:0030512            | Negative regulation of transforming growth factor β receptor signaling pathway | Biological process            | 7     | 4.81x10^-3 | DAND5, ADAMTSL2, ZNF451, CHST11, TGFB1I1I, PRDM16 and TGFB1I1         |
| GO:0072207            | Metanephric epithelium development                                          | Biological process            | 3     | 5.74x10^-3 | WNT7B, OSRI and PAX2                                                  |
| GO:0070507            | Regulation of microtubule cytoskeleton organization                         | Biological process            | 4     | 6.52x10^-3 | DIXDC1, CDK5R1, ATAT1 and EFNA5                                      |
| GO:0045216            | Cell-cell junction organization                                             | Biological process            | 4     | 9.16x10^-3 | CLDN9, CLDN6, MARVELD3 and TGFB1                                      |
| GO:0008285            | Negative regulation of cell proliferation                                    | Biological process            | 19    | 9.45x10^-3 | TP53II11, NACC2, CLMN, KLF10, FGFRL1, TP53, GPER1, ZEB1, CBFA2I3 and TGFB1 |
| GO:0031497            | Chromatin assembly                                                          | Biological process            | 3     | 1.53x10^-2 | CDAN1, TP53 and CHAF1A                                                |
| GO:0006366            | Transcription from RNA polymerase II promoter                                | Biological process            | 22    | 1.62x10^-2 | MAF, MAFF, FOXL2, POLR2L, MAFB, SOX12, TP53, ARID3B, FOSB and NAPSA4 |
| GO:0008104            | Protein localization                                                        | Biological process            | 6     | 1.69x10^-2 | TN54, MALL, CDAN1, TP53, GRASP and AKAP3                               |
| GO:0000122            | Negative regulation of transcription from RNA polymerase II promoter        | Biological process            | 28    | 1.98x10^-2 | NR6A1, CBX2, ZEB1, PRDM16, ZNF345, TGFB1I1I, KANK2, AHRR, EZR and OSR1 |
| GO:0030054            | Cell junction                                                               | Cellular component            | 24    | 6.45x10^-4 | SH3PXD2B, ARC, DLGAP1, ACHE, SH3PXD2A, CACNG8, SYT11, GRIK5, LRRCC4B and BSN |
| GO:0014069            | Postsynaptic density                                                        | Cellular component            | 13    | 1.51x10^-3 | DLGAP1, ARC, CDK5R1, CACNG8, SYT11, GRIK5, BSN, GPER1, SHANK3 and CNH2 |
| GO:0005737            | Cytoplasm                                                                   | Cellular component            | 152   | 2.33x10^-3 | RBPMS2, STIL, PLXNA1, ATP1B2, LRRCC4B, MED22, CALB2, TGFB1, KANK2 and PACSIN1 |
| GO:0043197            | Dendritic spine                                                             | Cellular component            | 9     | 2.60x10^-3 | CDK5R1, ARC, CTTCN, CNH2, SYT11, DLG4, ACIS2, SEZ6 and SHANK3          |
| GO:0044297            | Cell body                                                                   | Cellular component            | 7     | 3.72x10^-3 | GNAZ, EZR, SYT11, PACRG, FADD, DISC1 and EPO                           |
| GO:0005634            | Nucleus                                                                     | Cellular component            | 151   | 1.30x10^-2 | ALAD, PLXNA1, ZNF451, ZNF250, CBX2, RNF216, IPK2B, CALB2, TGFB1 and ANKI |
| GO:0030424            | Axon                                                                        | Cellular component            | 12    | 1.72x10^-2 | CDK5R1, ATAT1, STMN3, SYT11, FKBPI5, LMTK3, BSN, GPER1, LDLRAP1 and KIF21B |
| GO:0005884            | Actin filament                                                               | Cellular component            | 6     | 1.89x10^-2 | CTTCN, EZR, APC2, AIF1I, FKBPI5 and MYO9B                               |
| GO:0005886            | Plasma membrane                                                             | Cellular component            | 115   | 3.45x10^-2 | KCNC1, SLC9A8, ALPPL2, PLXNA1, ATP1B2, EFNA2, C6ORF25, FGFRL1, GRIK5 and TLR6 |
| GO:0048471            | Perinuclear region of cytoplasm                                             | Cellular component            | 23    | 4.02x10^-2 | CDK5R1, ACHE, STC2, APC2, CSF1, BRSK2, VP553, MYO9B, GPER1 and NDOR1   |
Table IV. Continued.

| Term          | Description                                                                 | Type            | Count | P value   | Genes                                                                 |
|---------------|------------------------------------------------------------------------------|-----------------|-------|-----------|-----------------------------------------------------------------------|
| GO:0001228    | Transcriptional activator, activity RNA polymerase II transcription regulatory region sequence-specific binding | Molecular function | 8     | 8.50x10^-3 | MAF, MAFF, DLX2, MAFB, FOXF1, TP53, NEUROD2 and ARID3B               |
| GO:0046872    | Metal ion binding                                                            | Molecular function | 68    | 8.68x10^-3 | GNAZ, STEAP3, SGSH, ALPPL2, ALAD, ZNF451, SOBP, ZNF250, RNF216 and ZEB1 |
| GO:0000978    | RNA polymerase II core promoter proximal region sequence-specific DNA binding | Molecular function | 17    | 1.37x10^-2 | FOXL2, TBX15, NACC2, TBX2, MAFB, NR6A1, ARID3B, FOSB, Npas4 and DDN   |
| GO:0048495    | Roundabout binding                                                           | Molecular function | 3     | 1.90x10^-2 | MYO9B, TGFB1I1 and TPBGL                                              |
| GO:003779     | Actin binding                                                                | Molecular function | 14    | 1.90x10^-2 | EPS15L1, Sfn, SLC9A3R2, TNKS1BP1, PAK6, CTTN, EPB41L1, EFNB1 and NEDD4 |
| GO:0030295    | Protein kinase activator activity                                             | Molecular function | 4     | 2.46x10^-2 | DUSP19, MADD, RPTOR and EPO                                            |
| GO:0098641    | Cadherin binding involved in cell-cell adhesion                               | Molecular function | 14    | 2.58x10^-2 | EPS15L1, Sfn, SLC9A3R2, TNKS1BP1, PAK6, CTTN, EPB41L1, EFNB1 and NEDD4 |
| GO:0016874    | Ligase activity                                                              | Molecular function | 13    | 3.31x10^-2 | DTX3L1, PPL2, ZNF451, RNF216, ZNRF1, TLT1L11, RNF165, NEURL1B, PELI2 and NEDD4L |
| GO:0030276    | Clathrin binding                                                             | Molecular function | 5     | 3.75x10^-2 | TOM1L2, SYT11, RPH3AL, C2CD4C and LDRAP1                              |
| GO:004314     | [acyl-carrier-protein] S-malonyltransferase activity                         | Molecular function | 2     | 4.81x10^-2 | MCAT and FASN                                                          |
| hsa04910      | Insulin signaling pathway                                                    | KEGG pathway     | 8     | 2.79x10^-3 | CBBL, SOS1, PRKAB2, MAPK8, RPS6KB1, SOCS4, PRKACB and PPARC1A          |
| hsa04068      | FoxO signaling pathway                                                       | KEGG pathway     | 7     | 1.01x10^-2 | NLK, SOS1, PRKAB2, MDM2, FBXO32, MAPK8 and FOXO3                      |
| hsa04931      | Insulin resistance                                                           | KEGG pathway     | 6     | 1.62x10^-2 | RPS6KA2, PRKAB2, MAPK8, RPS6KB1, OGT and PPARC1A                      |
| hsa05205      | Proteoglycans in cancer                                                      | KEGG pathway     | 8     | 1.98x10^-2 | CBBL, CTTN, ERBB4, SOS1, MDM2, RPS6KB1, PRKACB and FZD4               |
| hsa04012      | ErbB signaling pathway                                                       | KEGG pathway     | 5     | 3.14x10^-2 | CBBL, ERBB4, SOS1, MAPK8 and RPS6KB1                                  |
| hsa04010      | MAPK signaling pathway                                                       | KEGG pathway     | 8     | 6.08x10^-2 | RPS6KA2, ARRB1, NLK, SOS1, FGFI3, MAPK8, PRKACB and MAP3K13            |
| hsa040410     | β-Alanine metabolism                                                         | KEGG pathway     | 3     | 6.72x10^-2 | ALDH6A1, ALDH1B1 and EHHADH                                           |
| hsa0512       | Mucin type O-Glycan biosynthesis                                             | KEGG pathway     | 3     | 6.72x10^-2 | GALNT4, GALNT1B and B4GALT5                                           |
| hsa04920      | Adipocytokine signaling pathway                                              | KEGG pathway     | 4     | 7.13x10^-2 | PRKAB2, MAPK8, PPARC1A and CAMKK2                                    |
| hsa04917      | Prolactin signaling pathway                                                  | KEGG pathway     | 4     | 7.13x10^-2 | SOS1, MAPK8, SOCS4 and FOXO3                                          |

Only 10 genes were listed as examples in each pathway. GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; MAPK, mitogen-activated protein kinase; FoxO, Forkhead box O.
| miRNA   | Geneset | Description                              | Count | P-value | E     | Overlapping genes                                           | URL                                                                 |
|---------|---------|------------------------------------------|-------|---------|-------|-------------------------------------------------------------|----------------------------------------------------------------------|
| miR-663a-5p | P00037  | Ionotropic glutamate receptor pathway    | 3     | 0.0852  | 1.05  | GRIK5, SLC1A7 and SHANK3                                     | http://www.pantherdb.org/pathway/pathwayDiagram.jsp?catAccession=P00037 |
|         | P02743  | Fomyltetrahydroformate biosynthesis      | 1     | 0.1319  | 0.14  | MTR                                                        | http://www.pantherdb.org/pathway/pathwayDiagram.jsp?catAccession=P02743 |
|         | P04392  | P53 pathway feedback loops 1            | 1     | 0.1319  | 0.14  | TP53                                                       | http://www.pantherdb.org/pathway/pathwayDiagram.jsp?catAccession=P04392 |
|         | P00012  | Cadherin signaling pathway               | 6     | 0.1412  | 3.56  | PCDHA8, CDH23, WNT7B, FZD1, FZD4 and CELSR1                | http://www.pantherdb.org/pathway/pathwayDiagram.jsp?catAccession=P00012 |
|         | P05726  | 2-arachidonoylglycerol biosynthesis      | 1     | 0.1522  | 0.16  | DAGLA                                                      | http://www.pantherdb.org/pathway/pathwayDiagram.jsp?catAccession=P05726 |
|         | P00020  | FAS signaling pathway                   | 2     | 0.1614  | 0.72  | DFFB and FADD                                              | http://www.pantherdb.org/pathway/pathwayDiagram.jsp?catAccession=P00020 |
|         | P00029  | Huntington disease                      | 5     | 0.1702  | 2.96  | ARL4C, DLG4, GRIK5, PACSIN1 and TP53                      | http://www.pantherdb.org/pathway/pathwayDiagram.jsp?catAccession=P00029 |
|         | P00057  | Wnt signaling pathway                   | 9     | 0.2380  | 6.84  | APC2, PCDHA8, CDH23, TP53, WNT7B, FZD1, FZD4, KREMEN1 and CELSR1 | http://www.pantherdb.org/pathway/pathwayDiagram.jsp?catAccession=P00057 |
|         | P00045  | Notch signaling pathway                 | 2     | 0.2383  | 0.93  | HEYL and HES2                                              | http://www.pantherdb.org/pathway/pathwayDiagram.jsp?catAccession=P00045 |
|         | P02746  | Heme biosynthesis                       | 1     | 0.2467  | 0.28  | ALAD                                                       | http://www.pantherdb.org/pathway/pathwayDiagram.jsp?catAccession=P02746 |
| miR-154-3p | P00032  | Insulin/IGF pathway-MAPK kinase/MAPK cascade | 3     | 0.0116  | 0.48  | RPS6KA2, RPS6KB1 and SOS1                                   | http://www.pantherdb.org/pathway/pathwayDiagram.jsp?catAccession=P00032 |
|         | P06959  | CCKR signaling map                      | 7     | 0.0231  | 2.92  | FOXO3, CXCL2, PRKACB, MAPK8, RPS6KB1, SOS1 and TAC1       | http://www.pantherdb.org/pathway/pathwayDiagram.jsp?catAccession=P06959 |
|         | P04372  | 5-Hydroxytryptamine degradation         | 2     | 0.0351  | 0.30  | ALDH1L2 and ALDH1B1                                        | http://www.pantherdb.org/pathway/pathwayDiagram.jsp?catAccession=P04372 |
|         | P00018  | EGF receptor signaling pathway          | 5     | 0.0398  | 1.92  | ERBB4, MAPK8, SOS1, CBLB and PHLD2                        | http://www.pantherdb.org/pathway/pathwayDiagram.jsp?catAccession=P00018 |
|         | P00048  | PI3K pathway                            | 3     | 0.0420  | 0.78  | FOXO3, RPS6KB1 and SOS1                                     | http://www.pantherdb.org/pathway/pathwayDiagram.jsp?catAccession=P00048 |
|         | P04397  | p53 pathway by glucose deprivation      | 2     | 0.0467  | 0.35  | PRKAB2 and RPS6KB1                                         | http://www.pantherdb.org/pathway/pathwayDiagram.jsp?catAccession=P04397 |
miRNAs, and circRNAs, which were newly revealed to have similar regulatory functions, particularly to miRNAs, were indicated to also serve crucial roles (44,93-97). Abnormal expression of a large number of miRNAs has been determined in malignant tumor tissues (98-100). For example, it has been reported that miR-221/miR-222 and miR-15b serve a role in causing malignant tumors (101). Additionally, it was determined that miR-451 and miR-126 have an abnormal expression in lung cancer (102), and the targeted delivery of miRNA therapeutics was a promising strategy for cancer (103). This abnormal expression pattern affects the occurrence, development and prognosis of the tumor by directly regulating the biological functions of the targeted mRNAs (102,104-112). Studies have demonstrated that a variety of miRNAs exhibit abnormal expression patterns in pancreatic cancer cells that affect the occurrence, development and prognosis of pancreatic cancer; for example, the upregulated expression of miR-10b, miR-21, miR23a and miR-27a in pancreatic cancer affects cell growth, proliferation and apoptotic metastasis by targeting programmed cell death 4, BTG anti-proliferation factor 2, neural precursor cell expressed, developmentally downregulated 4-like, phosphatase and tensin homolog, HIV-1 Tat interactive protein 2 and p16 (113-117).

With the increased understanding of the regulatory mechanism of ncRNAs, ceRNAs have attracted increasing attention as important regulators of miRNA activity. ceRNA
Table VI. ceRNAs and their sequences of miR-663a-5p and miR-154-3p.

| miRNA   | ceRNA        | Sequences                                                                 |
|---------|--------------|---------------------------------------------------------------------------|
| miR-663a-5p | hsa_circ_0003176 | 5'-ACATGGAGCTGCACAGAATGTCAAGAAAGCACAGAAG ACC CCG CCG CAC AGG GC-3' |
|         | hsa_circ_0048579 | 5'-TTCCCTAGGGTTAAAAACCAAAACAGGGGAGGAAGAAAAAGCAAGTTCTCCGGGGCTTGGCGTGTA-3' |
|         | hsa_circ_0063706 | 5'-ACTGGTCAAGTGAGTGCAGGGAGAAGAGAGAAGATGCCATTCAACTCCAGGATGGC-3' |
|         | hsa_circ_0071922 | 5'-GACCTCTCAGGGTTACCCATGAAATATATATAGAAAAAGCAACACATAAACCAATGCGGAT-3' |
|         | hsa_circ_0079319 | 5'-TTTGAATGTTGAAATAAAAGCATCATGTAATTTACCGAACGCCGCTACAGGTCAGAAG-3' |
|         | hsa_circ_0083080 | 5'-TCATTCTATTATTATTAAAGGTTCAAACCAACGCCCCTGGGAGCGGCGGAC-3' |
|         | hsa_circ_0089643 | 5'-CGTCAACGGGCAGTTACTACACGGGAAAGTGCTGCGTGGTCGAGTCACAAGGGCAGGG-3' |
|         | hsa_circ_0090372 | 5'-GGCACCAATTTAAAGGGGCTGAAAGTCTGAGCTCTGGCCGGCCCCCCGAGTTGCTCCGCG-3' |
|         | RP11-59C5.3   | 5'-CTGTTTTTGGCATGAGCAAGAGAAGATGTGGAAAGATTTGATTTTAGAATTTAAACGCGCTTTGGAAC-3' |
|         | RP13-516M14.8 | 5'-AAACACCTGCTAGATTTTCTAGACCTGAGACTGTTGGACGAAAGCTGAGATATTACAGAATG-3' |
|         | RP11-196G18.24 | 5'-CGCTCACAGTGATCGTGATAGGTACAAATGATACAGCTCGTATCTGTCGAGTTGACGC-3' |
|         | AJ006995.3    | 5'-GGGAACAAATTTATCCTGTAGAAAGAGATGTGATAGGTGATAGTAGATACGTGGTGC-3' |
|         | AC024560.2    | 5'-TCACCCAGAATATCTTCTGGAGACATAAATCACTCCTCGAATTTAAACGACAGAAGCTAA-3' |
|         | PPPR1C        | 5'-ACTTTCTTTCGAGTATACCCGATCCCTCACTGTTTCCGAGACCTCGAATGTTTAAATTTAAAATACCA-3' |
|         | LINC00595     | 5'-GCTGGCAATCTAACCGGCTTTGTTAATTACTATATATATATCCCAGAAAGAAATGAAATCAGGAGG-3' |
|         | HAGLROS       | 5'-GAAGTGGCTTAAAGCTGCTTGGAACCTGAGCCTCTAAATGAGTTATGAGAATGCTTAATTTAAAATACCA-3' |
| miR-154-3p | hsa_circ_0000156 | 5'-TGCTTTTCTAGAATCCATAGTTGAAAGATGTGGTCTTTTTCTATGCGAGGTGGAATAGCACAAG-3' |
|         | hsa_circ_0004089 | 5'-CACCTGCAATGAGAAAAAAAGGAGACACTAACAAAACACTGGAATAAAGGATACCTGATGATG-3' |
|         | hsa_circ_000646 | 5'-GAATATAGTCGAGCTATACGCTGTTGAAGCTGAGCAGTCCTAACGTAATGTTATGAGAATGCTTAATTTAAAATACCA-3' |
|         | hsa_circ_0015157 | 5'-GGGAACAAATTTATCCTGTAGAAAGAGATGTGATAGGTGATAGTAGATACGTGGTGC-3' |
|         | hsa_circ_0058665 | 5'-TAAAAAAATGTTTGAGGTGAAATATGCTGATGAAATAGCTGTTCATGTAATGCTGAGACATG-3' |
|         | RP11-68606.1  | 5'-CCCTGGCTTTATGATGGAATATATACGTCATGTAATGCTGATGAAATAGCTGTTCATGTAATGCTGAGACATG-3' |
|         | LINC01140     | 5'-CAGATGGGGGTGAAATCTCCCTCAGAAATGCGAGTCCTGTTAATTAAATTAACAGTGTCGCA-3' |

miR, microRNA; ceRNA, competitive endogenous RNA.
WEI et al: ceRNA NETWORKS IN AUTOPHAGY SUPPRESSION OF PANCREATIC CANCER

Refers to lncRNAs and circRNAs that suppress miRNA expression through targeted binding to the miRNA, and thus regulate its activity, which affects the development, progression and prognosis of tumors (118-120). Studies have indicated that lncRNA-metastasis associated lung adenocarcinoma transcript 1 can target miR-124 to reduce its expression and activate cyclin-dependent kinase 4, thereby accelerating the progression of breast cancer (121-123). A recent study on pancreatic cancer demonstrated that lncRNA-urolithic cancer associated 1 was overexpressed in pancreatic cancer tissues and reduced miR-135a expression by adsorbing it, thereby inhibiting genes associated with tumor growth and metastasis (124). These examples highlight the significance of the interactions among lncRNAs, miRNAs and mRNAs for cancer diagnosis and treatment.

Therefore, our aim was to mine pancreatic cancer autophagy-associated ceRNAs and miRNAs through assays with ceRNA and miRNA microarrays, respectively, to reveal their targets using bioinformatics methods, construct ceRNA, miRNA and mRNA pathways, predict the potential molecular mechanisms of the ceRNA, miRNA and mRNA pathways in the autophagy of pancreatic cancer, and provide novel ideas and directions for further studies of pancreatic cancer.

Firstly, the differentially-expressed mRNAs were analyzed. The results demonstrated that PANC-1 cells treated with chloroquine diphosphate had multiple differentially-expressed mRNAs, compared with the control group, using the FC value $FC>2$ or $FC<0.5$ as the threshold. The bioinformatics analysis of these genes indicated that as the autophagic level changed, the differentially-expressed genes were primarily concentrated in tumor-associated and pancreatic cancer-associated pathways.

Figure 12. ceRNA network of miR-663a-5p. The predicted ceRNA of miR-663a-5p included 9 upregulated circRNAs, 8 upregulated lncRNAs, miR-663a-5p and 46 differentially-expressed mRNA, which were differentially expressed in the ceRNA microarray results as well. Nodes in green, yellow, red and blue represent circRNAs, lncRNAs, miR-663a-5p and mRNAs, respectively. miR, microRNA; circRNA, circular RNA; lncRNA, long non-coding RNA; ceRNA, competitive endogenous RNA.

![Figure 12](image12.png)

Figure 13. ceRNA network of miR-154-3p. The predicted ceRNA of miR-154-3p included 5 upregulated circRNAs, 2 upregulated lncRNAs, miR-154-3p and 11 differentially-expressed mRNA, which were differentially expressed in the ceRNA microarray results as well. Nodes in yellow, green, red and blue represent circRNAs, lncRNAs, miR-154-3p and mRNAs, respectively. The arrows indicate the direction of transcription. miR, microRNA; circRNA, circular RNA; lncRNA, long non-coding RNA; ceRNA, competitive endogenous RNA.

![Figure 13](image13.png)
is an autophagy-related protein that has been demonstrated to function as a key autophagy-associated target gene regulated by miR-23b, and suppression of ATG12 significantly increased the radiosensitivity of pancreatic cancer cells, whereas the miR-23b-induced radiosensitivity was eliminated by ATG12 overexpression (125). Studies indicated that ULK served an important role in the autophagy process (126-128). ULK2 and ULK1 are highly homologous, functionally complementary and indispensable for affecting autophagy (129 -131).

GABARAPL1 is considered as a target of miR-195 and regulates the proliferation, migration, angiogenesis and autophagy of endothelial progenitor cells (132). These three genes (ATG12, GABARAPL1 and ULK2) may serve pivotal roles in the autophagy suppressed by chloroquine diphosphate in pancreatic cancer cells.

To determine relevant miRNAs and elucidate their potential regulatory mechanisms in the autophagy of pancreatic cancer, differentially-expressed miRNAs were analyzed and their target genes were predicted. Subsequently, the results were compared with the target genes detected in the microarray analysis. The co-expressed genes were considered the putative target genes regulated by the abnormally-expressed miRNAs during the autophagy process in pancreatic cancer cells. Bioinformatics analyses were performed on these target genes to identify the signaling pathways and biological processes that were regulated. The results demonstrated that the expression of miR-663a-5p and miR-154-3p was downregulated in the PANC-1 cells treated with chloroquine diphosphate, compared with the control group. miR-663a-5p expression in pancreatic cancer tissues is significantly downregulated and negatively associated with eukaryotic translation elongation factor 1α2 (eEF1A2) expression due to miR-663 reducing the proliferation and invasion of pancreatic cells by directly targeting eEF1A2 in vitro and in vivo (133). Additionally, miR-663a-5p has been reported to have a low expression in hepatocellular carcinoma (134), non-small cell lung cancer (135) and colorectal cancer (136). Similarly, the present comprehensive analysis indicated that the expression of miR-663a-5p was
downregulated in pancreatic ductal adenocarcinoma (PDAC). In the present study, the bioinformatics analyses indicated that the putative autophagy pathways in the pancreatic cancer cells regulated by miR-663a-5p included the aldosterone-regulated sodium reabsorption, Wnt signaling, basal cell carcinoma, fatty acid biosynthesis and PI3K-Akt signaling pathways, of which the Wnt signaling and PI3K-Akt signaling pathways were considered to have a function in the regulation of autophagy (137-143). Currently, whether miR-154-3p is involved in the biological processes of pancreatic cancer cells, including occurrence, development, prognosis and autophagy, remains unknown; however, miR-154-3p was reported to be expressed at a low level in colorectal cancer and was associated with the degree of malignancy of colorectal cancer (144). Similarly, miR-154-3p exhibited low expression in breast cancer and affected the treatment outcome of breast cancer by regulating E2F transcription factor 5 (145). Additionally, the present comprehensive analysis indicated that the expression of miR-154-3p was downregulated in PDAC. Furthermore, the bioinformatics analyses indicated that the putative autophagy pathways in the pancreatic cancer cells regulated by miR-154-3p included the insulin signaling pathway, FoxO signaling, mitogen-activated protein kinase signaling, ErbB signaling, p53 pathway by glucose deprivation and CCKR signaling map pathways. Activation of insulin like growth factor 1 receptor (IGF-1R) signaling antagonizes the decrease in cell viability of human disc cells through the suppression of apoptosis and enhancement of autophagy (146). IGF-1R increases cell viability during hypoxia, which may be dependent on promoting autophagy by suppressing the PI3K/Akt/mTOR signaling pathway (147). The present study demonstrated that a number of genes, including suppressor of cytokine signaling 1 (SOCS1), plasma membrane intrinsic protein 3 (PIP3), serine/threonine protein phosphatase type 1 α (PP1), which were involved in the insulin signaling pathway, were abnormally expressed when the autophagic level was decreased. Overexpression of SOCS1 suppressed the PI3K/PIP3/Akt signaling pathway with the subsequent PP1 activation, which has been demonstrated to induce autophagy (148,149). Autophagy is inhibited under the condition of oxygen-glucose deprivation (150). Therefore, we hypothesized that miR-154-3p influences the key genes in the insulin signaling or p53 pathways by glucose deprivation, thereby affecting autophagy. Additionally, due to the involvement of CCKR signaling in pancreatic enzyme secretion (151,152), miR-154-3p may serve a key role in the secretion process. Therefore, the data in the present study will provide novel directions for the investigation of pancreatic cancer and its autophagy.

To elucidate which genes inhibited the miRNAs regulating the autophagy of pancreatic cancer cells through competitive binding, potential target associations between circRNA and miRNA, and between lncRNA-miRNA were predicted based on the competitive expression of ceRNA and miRNA. When these results were combined with the differentially-expressed circRNAs and IncRNAs under different autophagic levels detected by the microarrays, numerous ceRNAs that exhibited target associations with miR-663a-5p and miR-154-3p, and negative associations with the expression of the targeted miRNAs under the same changes in the autophagic level were determined. AC024560.2 is an effective lncRNA residing on chromosome 3 that can be used to predict the metastasis of early cervical cancer to lymph nodes (153). In the present study, AC024560.2 was determined to competitively bind to miR-663a-5p and thus regulate the autophagic level of pancreatic cancer cells by inhibiting the expression of this miRNA. For the other ceRNAs, their associations with tumors have not been reported, and further investigations are required.

Since the molecular mechanisms of tumor occurrence and development are complex and the numerous different physiological processes, including differentiation (154) and aging (155), are frequently accompanied by an aberrant autophagic level (156,157), it is not surprising that the interference of autophagy is determined to be one of the therapeutic methods for tumors. The growth of PDAC could be repressed by hydroxychloroquine in vivo and in vitro (158). PDAC was dependent on autophagy and the use of an autophagy inhibitor may become the breakthrough point of treatment (35). However, in the treatment of PDAC with gemcitabine, a high concentration of gemcitabine is required following adding autophagy inhibitors (37). Therefore, autophagy may serve a dual role in the development of PDAC. Investigating the ceRNA network following inhibiting autophagy, of which these genes may serve role in inhibiting autophagy or promoting autophagy, will provide novel ideas for determining new ways to treat pancreatic cancer. On this basis, the biological function and action mechanism of these two miRNAs will be investigated in further studies.

In summary, the miRNAs that were significantly associated with the autophagy of pancreatic cancer included miR-663a-5p and miR-154-3p. These miRNAs were used as the intermediate regulatory sites, upstream to which multiple putative ceRNAs, including AC024560.2, were present and downstream to multiple targeted regulatory genes, including ATG12 and ULK1. The expression of these miRNAs was regulated through ceRNA, miRNA and mRNA interactions, which could serve important regulatory roles in pancreatic cancer autophagy.

In conclusion, autophagy serves an important role in the development and progression of various malignant tumor types, including lung (159), gastric (160) and renal cancer (161). The investigation of differentially-expressed genes in pancreatic cancer cells under different autophagic levels not only clarifies the regulatory mechanism of the autophagic process in pancreatic cancer cells, but also provides novel ideas for the effective diagnosis and treatment of pancreatic cancer. In the present study, microarray technology was employed to confirm that the change in the autophagic level of pancreatic cancer cells was accompanied by various differentially-expressed genes. Following establishing multiple ceRNA, miRNA and mRNA associations, there is more reason to consider that these genes will serve important roles in the diagnosis and treatment of pancreatic cancer, and thus lay the theoretical foundation for subsequent investigations on pancreatic cancer while indicating new research directions. Subsequently, the regulatory functions of these genes at the cellular and tissue levels will be investigated and their specificity and accuracy will be further validated through a series of in vivo and in vitro experiments.
Acknowledgments

The authors would like to thank all publicly available data used in the present study.

Funding

The study was supported by the funds of the National Natural Science Foundation of China (grant no. NSFC81560448), the Natural Science Foundation of Guangxi, China (grant no. 2016GXNSFBA380039), Medical Excellence Award Funded by the Creative Research Development Grant from the First Affiliated Hospital of Guangxi Medical University, Guangxi Medical University Training Program for Distinguished Young Scholars, and the Promoting Project of Basic Capacity for University Young and Middle-aged Teachers in Guangxi (grant no. KY2016LX031). The funders had no role in the study design, the data collection and analysis, the decision to publish, or the preparation of the manuscript.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

DMW and MTJ wrote the paper, performed the experiments and conducted bioinformatics analysis. PL, HY and YWD wrote the paper and conducted bioinformatics analysis. QY and DYL conducted bioinformatics analysis and statistical data analysis. DZL and GC designed the project, supervised the experiments and corrected the draft.

Ethics approval and consent to participate

The present study was approved by the Ethics Committee of the First Affiliated Hospital of Guangxi Medical University, and all patients provided signed informed consent.

Ethics approval and consent to publish

Consent for the publication of the pathological data was obtained from all patients who were involved in the present study.

Competing interests

The authors declare that they have no competing interests.

References

1. Ryan DP, Heng TS and Bardeesy N: Pancreatic adenocarcinoma. N Engl J Med 371: 2140-2141, 2014.
2. Swords DS, Firova MA, Scalfie CL and Mulvihill SJ: Biomarkers in pancreatic adenocarcinoma: Current perspectives. Oncotargets Ther 9: 7459-7467, 2016.
3. Siegel RL, Miller KD and Jemal A: Cancer Statistics, 2017. CA Cancer J Clin 67: 7-30, 2017.
4. Siegel RL, Miller KD and Jemal A: Cancer statistics, 2018. CA Cancer J Clin 68: 7-30, 2018.
5. Song HY, Wang Y, Lan H and Zhang YY: Expression of Notch receptors and their ligands in pancreatic ductal adenocarcinoma. Exp Ther Med 16: 53-60, 2018.
6. Xu Q, Gao J and Li Z: Identification of a novel alternative splicing transcript variant of the suppressor of fused: Relationship with lymph node metastasis in pancreatic ductal adenocarcinoma. Int J Oncol 49: 2611-2619, 2016.
7. Li Q, Zhang L, Li X, Yan H, Yang L, Li Y, Li T, Wang J and Cao B: The prognostic significance of human epidermal growth factor receptor family protein expression in operable pancreatic cancer: HER1-4 protein expression and prognosis in pancreatic cancer. BMC Cancer 16: 910, 2016.
8. Li H, Hao X, Wang H, Liu Z, He Y, Pu M, Zhang H, Yu H, Duan J and Qu S: Circular RNA Expression Profile of Pancreatic Ductal Adenocarcinoma Revealed by Microarray. Cell Physiol Biochem 40: 1334-1344, 2016.
9. Zhu L, Staley C, Kooby D, El-Rays B, Mao H and Yang L: Current status of biomarker and targeted nanoparticle development: The precision oncology approach for pancreatic cancer therapy. Cancer Lett 388: 139-148, 2017.
10. Kocaturk NM and Gouzuicki C: Crossover Between Mammalian Autophagy and the Ubiquitin-Proteasome System. Front Cell Dev Biol 6: 128, 2018.
11. Hong JC, Czito BG, Willett CG and Palma M: A current perspective on stereotactic body radiation therapy for pancreatic cancer. Oncotargets Ther 9: 6733-6739, 2016.
12. Marsoner K, Haybaecck J, Csengeri D, Waha JE, Schager J, Langeder R, Mischinger HJ and Kornprat P: Pancreatic resection for intraductal papillary mucinous neoplasms - a ten-year single center experience. BMC Cancer 16: 844, 2016.
13. Jiang MY, Jang JY and Kim SW: Surgical resection of pancreatic head cancer: What is the optimal extent of surgery? Cancer Lett 382: 259-265, 2016.
14. Ellerhoff TP, Berchtold S, Venturelli S, Burkard M, Smirnov I, Wulff T and Lauer UM: Novel epi-virotherapeutic treatment of pancreatic cancer combining the oral histone deacetylase inhibitor resminostat with oncolytic measles virus vaccine. Int J Oncol 49: 1931-1944, 2016.
15. Zuo C, Sheng X, Ma M, Xia M and Ouyang L: ISG15 in the tumorigenesis and treatment of cancer: An emerging role in malignancies of the digestive system. Oncotarget 7: 74393-74409, 2016.
16. Chang JH, Jiang Y and Pillarisetty VG: Role of immune cells in pancreatic cancer from bench to clinical application: An updated review. Medicine (Baltimore) 95: e5541, 2016.
17. Kim KH and Lee MS: Autophagy--a key player in cellular and body metabolism. Nat Rev Endocrinol 10: 322-337, 2014.
18. Tao Z, Li T, Ma H, Yang Y, Zhang C, Hai L, Liu P, Yuan F, Li J, Yi L, et al: Autophagy suppresses self-renewal ability and tumorigenicity of glioma-initiating cells and promotes Notch1 degradation. Cell Death Dis 9: 1063, 2018.
19. Mowers EE, Shariff MN and Macleod KF: Autophagy in cancer metastasis. Oncogene 36: 1619-1630, 2017.
20. Tan YQ, Zhang J and Zhou G: Autophagy and its implication in human oral diseases. Autophagy 13: 225-236, 2017.
21. Green DR, Oguin TH and Martinez J: The clearance of dying cells: Table for two. Cell Death Differ 23: 915-926, 2016.
22. Sionov RV, Vlahopoulos SA and Granot Z: Regulation of Bim in melanoma. Cell Death Dis 9: 1063, 2018.
23. Chang JH, Jiang Y and Pillarisetty VG: Role of immune cells in pancreatic cancer from bench to clinical application: An updated review. Medicine (Baltimore) 95: e5541, 2016.
24. Kim KH and Lee MS: Autophagy--a key player in cellular and body metabolism. Nat Rev Endocrinol 10: 322-337, 2014.
25. Tao Z, Li T, Ma H, Yang Y, Zhang C, Hai L, Liu P, Yuan F, Li J, Yi L, et al: Autophagy suppresses self-renewal ability and tumorigenicity of glioma-initiating cells and promotes Notch1 degradation. Cell Death Dis 9: 1063, 2018.
26. Mowers EE, Shariff MN and Macleod KF: Autophagy in cancer metastasis. Oncogene 36: 1619-1630, 2017.
27. Tan YQ, Zhang J and Zhou G: Autophagy and its implication in human oral diseases. Autophagy 13: 225-236, 2017.
28. Green DR, Oguin TH and Martinez J: The clearance of dying cells: Table for two. Cell Death Differ 23: 915-926, 2016.
29. Sionov RV, Vlahopoulos SA and Granot Z: Regulation of Bim in melanoma. Cell Death Dis 9: 1063, 2018.
30. Chang JH, Jiang Y and Pillarisetty VG: Role of immune cells in pancreatic cancer from bench to clinical application: An updated review. Medicine (Baltimore) 95: e5541, 2016.
31. Kim KH and Lee MS: Autophagy--a key player in cellular and body metabolism. Nat Rev Endocrinol 10: 322-337, 2014.
28. Vera-Ramirez L, Vodnala SK, Nini R, Hunter KW and Green JE: Autophagy promotes the survival of dormant breast cancer cells and metastatic tumour recurrence. Nat Commun 9: 1944, 2018.

29. Li SJ, Sun SJ, Gao J and Sun FB: Wogonin induces Beclin-1/PI3K and reactive oxygen species-mediated autophagy in human pancreatic cancer cells. Oncol Lett 12: 5059-5067, 2016.

30. Klein K, Werner K, Teske C, Schenk M, Giese T, Weitz J and Welsch T: Role of TFE3-driven autophagy regulation in pancreatic cancer treatment. Int J Oncol 49: 164-172, 2016.

31. Kwon HJ, Quirin KA, Wek RC, Korc M, Yin XM and Kota J: Novel role of miR-29a in pancreatic cancer autophagy and its therapeutic potential. Oncotarget 7: 71635-71650, 2016.

32. Ranjan A and Srivastava SK: Penfluridol suppresses pancreatic tumor growth by autophagy-mediated apoptosis. Sci Rep 6: 36759, 2016.

33. Seo JW, Choi J, Lee SY, Sung S, Yoo HJ, Kang MJ, Cheong H and Son J: Autophagy is required for PDAC glutaminolysis metabolism. Sci Rep 6: 37594, 2016.

34. Yan Y, Jiang K, Liu P, Zhang X, Dong X, Gao J, Liu Q, Barr MP, Zhang Q, Hou X, et al: Batimolycin A1 induces caspase-independent cell death in hepatocellular carcinoma cells via targeting of autophagy and MAPK pathways. Sci Rep 6: 37052, 2016.

35. Yang S, Wang X, Contino G, Lisesa M, Sahin E, Ying H, Bause A, Li Y, Stomell JM, Dell’Antonio G, et al: Pancreatic cancers require autophagy for tumor growth. Genes Dev 25: 717-729, 2011.

36. Yang A, Arter-Hoppe G, Zhang H, Lin EY, Biancur D, Wang X, Deng J, Hai J, Yang S, Wong KK, et al: Autophagy sustains pancreatic cancer growth through both cell autonomous and non-autonomous mechanisms. Cancer Discov 8: 276-287, 2018.

37. Mikulskas J, Sitar A and Ku Y: The role of autophagy in the treatment of pancreatic cancer with gemcitabine and ionizing radiation. Int J Oncol 37: 821-828, 2010.

38. Marinkovic M, Sprung M, Buljubasic M and Novak A: Autophagy Modulation in Cancer: Current Knowledge on Action and Therapy. Oxid Med Cell Longev 2018: 803821, 2018.

39. Islam MA, Reesor EK, Xu Y, Zope HR, Zetter BR and Shi J: Biomaterials for mRNA delivery. Biomater Sci 3: 1519-1533, 2015.

40. Liu F, Gao S, Yang Y, Zhao X, Fan Y, Ma W, Yang D, Yang A and Yu Y: Akt and tumor activity of curcumin by modulation of apoptosis and autophagy in human lung cancer A549 cells through inhibiting PI3K/Akt/mTOR pathway. Oncol Rep 39: 1523-1531, 2018.

41. Chen JF, Wu P, Xia R, Yang J, Huo XY, Gu DY, Tang CJ, De W and Yang F: STAP3-induced IncRNA HAGLROS overexpression contributes to the malignant progression of gastric cancer cells via mTOR signal-mediated inhibition of autophagy. Mol Med 17: 6, 2018.

42. Gong J, Muñoz AR, Chan D, Ghosh R and Kumar AP: STAP3 downregulates LC3 to inhibit autophagy and pancreatic cancer cell growth. Oncol Rep 25: 2829-2841, 2011.

43. Raimondi M, Cesselli D, Di Loreto C, La Marra F, Schneider C and Demarchi F: USP1 (ubiquitin specific peptidase 1) targets ULK1 and regulates its cellular compartmentalization and autophagy. Autophagy: Oct 18, 2018 (Epub ahead of print).

44. Pan Y, Li C, Chen J, Zhang K, Chu X, Wang R and Chen L: The Emerging Roles of Long Noncoding RNA ROR (lincRNA-ROR) and its Possible Mechanisms in Human Cancers. Cell Physiol Biochem 40: 219-229, 2016.

45. Bamodu OA, Huang WC, Lee WH, Wu A, Wang LS, Hsiao M, Yeh CT and Chao TY: Aberrant KDM5B expression contributes to the malignant progression of gastric cancer cells via miR-1242/PDASH pathway. Int J Oncol 47: 705-717, 2015.

46. Zhang Q, Hou X, Dai L, Fu X, Zhang J and Ao Y: Circular RNA Related to the Chondrocyte ECM Regulates MMP13 Expression by Functioning as a miR-136 ‘Sponge’ in Human Cartilage Degradation. Sci Rep 6: 22572, 2016.

47. Xie H, Ren X, Xin S, Lan X, Lu G, Lin Y, Yang S, Zeng Z, Liao W, Ding YQ, et al: Emerging roles of circRNA_001569 targeting miR-145 in the proliferation and invasion of colorectal cancer. Oncotarget 7: 26680-26691, 2016.

48. Zhang Z, Ly M and Chen J: Screening differential circular RNA expression profiles reveals the regulatory role of circTF2C25-miR-103a-3p/miR-107-CDK6 pathway in bladder carcinoma. Sci Rep 6: 30919, 2016.

49. Li X, Feng X, Zheng M, Xie X, Lin H, Xu G, Fan Z, Zhang H, Gao M, et al: PM2.5 exposure-induced autophagy is mediated by IncRNA loc146880 which also promotes the migration and invasion of lung cancer cells. Biochim Biophys Acta, Gen Subj 1861: 112-125, 2017.

50. Li C, Zhao Z, Zhou Z and Liu R: Lnc-ROR confers gemcitabine resistance to pancreatic cancer cells via inducing autophagy and modulating the miR-124/PTBP1/PKM2 axis. Cancer Chemother Pharmacol 78: 1199-1207, 2016.

51. Chen ZH, Wang WT, Huang F, Kang S, Sun YM, Liu SR, Luo XQ and Chen YQ: The IncRNA HOTAIR1M regulates the degradation of PML-RARA oncoprotein and myeloid cell differentiation by enhancing the autophagy pathway. Cell Death Differ 24: 212-224, 2017.

52. Pawar K, Hanisch C, Palma Vera SE, Einspahr R and Shariat B: Down regulated IncRNA MEG3 eliminates mycobacteria in macrophages via autophagy. Sci Rep 6: 19416, 2016.

53. Vega-Rubin-de-Celis S, Zou Z, Fernandez AF, Ci B, Kim M, Xiao G, Xie Y and Levine B: Increased autophagy blocks HER2-mediated breast tumorigenesis. Proc Natl Acad Sci USA 115: 4176-4181, 2018.

54. Zarzynska JM: The importance of autophagy regulation in breast cancer development and treatment. BioMed Res Int 2014: 710345, 2014.

55. Qin W, Li C, Zheng W, Guo Q, Zhang Y, Kang M, Zhang B, Yang L, Li B, Yang H, et al: Inhibition of autophagy promotes metastasis and glycolysis by inducing ROS in gastric cancer cells. Oncotarget 6: 39845-39854, 2015.

56. Li C, Li R, Xu X, Zhang L, Rian F, Lian G, Huang Y, Feng X, Liu X, Li X, et al: CK11 suppresses lung tumour growth by stabilizing PTEN and inducing autophagy. Nat Cell Biol 20: 465-478, 2018.

57. Chen PM, Gombart ZJ and Chen JW: Chloroquine treatment of ARPE-19 cells leads to lysosomal dilation and intracellular lipid accumulation: possible implications of lysosomal dysfunction in macular degeneration. Cell Biosci 1: 10, 2011.

58. Li ML, Xu YZ, Lu WJ, Li YH, Tan SS, Lin HJ, Wu TM, Li Y, Yang SY and Zhao YL: Chloroquine potentiates the anti-cancer effect of sunitinib on renal cell carcinoma by inhibiting autophagy and inducing apoptosis. Onc Lett 15: 2839-2846, 2018.

59. Maragkakis M, Vergoulis T, Alexiou P, Reczko M, Plomaritou K, Gousis M, Kourtis K, Koziris N, Dalamagas T and Hatzigeorgiou AG: DIANA-microT Web server upgrade supports Fly and Worm miRNA target prediction and bibliographic miRNA to disease association. Nucleic Acids Res 39: W145-W148, 2011.

60. Plomaritou K, Gousis M, Kourtis K, Koziris N, Dalamagas T and Hatzigeorgiou AG: DIANA-microT web server v5.0: Service integration into miRNA functional analysis workflows. Nucleic Acids Res 39: W145-W148, 2011.
et al: MiR-30a-5p suppresses cell growth and

et al: Comprehensive microRNA target prediction online. Nucleic Acids Res 41 (Web Server issue): W165-W168, 2013.

Vejnar CE, Blum M and Zdobnov EM: miRmap web: Comprehensive microRNA target prediction online. Nucleic Acids Res 36 (Database): D165-D169, 2008.

Krek A, Grün D, Poy MN, Wolf R, Rosenberg L, Epstein EJ, MacMenamin P, da Piedade I, Gunsalus KC, Stoffel M, et al: Combinatorial microRNA target predictions. Nat Genet 37: 495-500, 2005.

Kertesz M, Iovino N, Unnerstall U, Gaul U and Segal E: The role of site accessibility in microRNA target recognition. Nat Genet 39: 1278-1284, 2007.

Miranda KC, Huynh T, Tay Y, Ang YS, Tam WL, Thomson AM, Lim BD and Rigoutsos I: A pattern-based method for the identification of MicroRNA binding sites and their corresponding heteroduplexes. Cell 126: 1203-1217, 2006.

Mikaelsevich V and Orkin SH: Characterization of the homo-polymmer tailing reaction catalyzed by terminal deoxynucleotidyl transferase. Implications for the cloning of cDNA. J Biol Chem 257: 14773-14782, 1982.

Hoshino T and Inagaki F: A comparative study of microribosomal diversity and community structure in marine sediments using poly(A) tailing and reverse transcription-PCR. Front Microbiol 4: 160, 2013.

Tajadini M, Panjehpour M and Javannard SH: Comparison of SYBR Green and TaqMan methods in quantitative real-time polymerase chain reaction analysis of four adenosine receptor subtypes. Adv Biomed Res 3: 85, 2014.

Mardis E and McCombie WR: Library Quantification Using SYBR Green-Quantitative Polymerase Chain Reaction (qPCR). Cold Spring Harb Protoc 2017: pdb prot94714, 2017.

Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001.

Huang W, Sherman BT and Lempicki RA: Bioinformatics enrichment tools: Paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 37: 1-13, 2009.

Kang MJ, Jang JY, Chang YR, Kwon W, Jung W and Kim SW: Comprehensive analysis of differentially expressed profiles of mRNAs, circRNAs and miRNAs during osteoclastogenesis. Sci Rep 6: 21399, 2016.

Huang M, Zhong Z, Lv M, Shu J, Tian Q and Chen J: Comprehensive analysis of differentially expressed profiles of IncRNAs and circRNAs with associated co-expression and ceRNA networks in bladder carcinoma. Oncotarget 7: 47186-47200, 2016.

Zhou X, Ye F, Yin C, Zhuang Y, Yue G and Zhang G: The Interaction Between MiR-141 and IncRNA-H19 in Regulating Cell Proliferation and Migration in Gastric Cancer. Cell Physiol Biochem 36: 1440-1452, 2015.

Zeng JH, Xiong DD, Pang YY, Zhang Y, Tang RX, Luo DZ and Chen G: Identification of molecular targets for esophageal carcinoma diagnosis using miRNA-seq and RNA-seq data from The Cancer Genome Atlas: A study of 187 cases. Oncotarget 8: 35681-35699, 2017.

Massillo C, Dalton GN, Farré PL, De Luca P and De Siervi A: Implications of microRNA dysregulation in the development of prostate cancer. Reproduction 154: R81-R97, 2017.

Murray MJ, Bell E, Raby KL, Riijlaards MA, Gillis AJ, Looijenga LH, Brown H, Destenaves B, Nicholson JC and Coleman N: A pipeline to quantify serum and cerebrospinal fluid microRNAs for diagnosis and detection of relapse in paediatric malignant cell-gum tumours. Br J Cancer 114: 151-162, 2016.

Ouyang Q, Xu L, Cui H, Xu M and Yi L: MicroRNAs and cell cycle of malignant glioma. Int J Neurosci 126: 1-9, 2016.

Díaz Vescovo V and Denti MA: microRNA and Lung Cancer. Adv Exp Med Biol 889: 153-177, 2017.

Rupaikoo R and Slack FJ: MicroRNA therapeutics: Towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov 16: 203-222, 2017.

Zhang X, Tang W, Chen G, Ren F, Liang H, Dang Y and Rong M: An Encapsulation of Gene Signatures for Hepatocellular Carcinoma, MicroRNA-132 Predicted Target Genes and the Corresponding Overlaps. PLoS One 11: e0159498, 2016.

Lan D, Zhang X, He R, Tang R, Li P, He Q and Chen G: MiR-133a is downregulated in non-small cell lung cancer: A Study of clinical significance of 20 miRNAs that regulate mealy metastases of pancreatic head cancer. Number of metastatic lymph nodes and lymph node ratio according to N stage. Ann Surg Oncol 21: 1545-1551, 2014.

Georgiadou D, Sergentanis TN, Sakellariou S, Vlachodimitropoulos D, Psaltopoulou T, Lazaris AC, Gounaris A and Zografos GC: Prognostic role of sex steroid receptors in pancreatic adenocarcinoma. Pathol Res Pract 212: 38-43, 2016.

Lovecck M, Skalicky P, Klos D, Bebarova L, Novral C, Cehman M, Zapletalova J, Svebsova H, Vrba R, Stasek M, et al: Long-term survival after resections for pancreatic ductal adenocarcinoma. Single centre study, Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 160: 280-286, 2016.

Ramaciatto G, Nigri G, Petrucciani N, Pinna AD, Ravoli M, Joggi E, Mazzini GL, Chirletti P, Tisonne G, et al: Pancreatocystectomy with Mesenteric and Portal Vein Resection for Borderline Resectable Pancreatic Cancer: Multicenter Study of 406 Patients. Ann Surg Oncol 23: 2028-2037, 2016.

Li PF, Chen SC, Xia T, Jiang XM, Shao YF, Xiao BX and Guo JM: Circulating miRNA profiles in gastric cancer. World J Gastroenterol 20: 5411-5419, 2014.

Kishikawa T, Otsuka M, Ohno M, Yoshikawa T, Takata A and Koike K: Circulating RNAs as new biomarkers for detecting pancreatic cancer. World J Gastroenterol 21: 8527-8540, 2015.

Bolton EM, Tuzova AV, Walsh AL, Lynch T and Perry AS: Noncoding RNAs in prostate cancer: the long and the short of it. Clin Cancer Res 20: 35-43, 2014.

Zhou X, Tang W, Ren R, Lan C, Xue X and Chen G: Downregulation of microRNA-212 indicates progression in hepatocellular carcinoma. Exp Ther Med 12: 2095-2101, 2016.
et al: Adipose tissue glycogen accumulation is a hallmark of pancreatic ductal adenocarcinoma: A meta-analysis. Eur J Cancer 51: 1389-1404, 2016.

113. Frampton AE, Castellano L, Colombo T, Giovannetti E, Krell J, Jacob J, Pellegrino L, Rosa-Alonso L, Funel N, Gall TM et al: MicroRNAs cooperatively inhibit a network of tumor suppressor genes to promote pancreatic tumor growth and progression. Gastroenterology 146: 268-277e18, 2014.

114. Frampton AE, Krell J, Jamieson NB, Gall TM, Giovannetti E, Funel N, Mato Prado M, Krell D, Habib NA, Castellano L, et al: microRNAs with prognostic significance in pancreatic ductal adenocarcinoma: A meta-analysis. Eur J Cancer 51: 1389-1404, 2016.

115. Giovannetti E, Funel N, Peters GJ, Del Chiaro M, Erozenzi L, Vassile E, Leon LG, Pollina LE, Groen A, Falcone A, et al: MicroRNA-21 in pancreatic cancer: Correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Cancer Res 70: 4528-4530, 2010.

116. Ouyang H, Gore J, Deitz S and Korc M: microRNA-10b enhances pancreatic cancer cell invasion by suppressing TIP30 expression and promoting EGF and TGF-β actions. Oncogene 33: 4666-4674, 2014.

117. Nakata K, Ohuchida K, Mizumoto K, Kayashima T, Ikenna N, Sakai H, Lin C, Fujita H, Otsuka A, Aishima S, et al: MicroRNA-10b is overexpressed in pancreatic cancer, promotes its invasiveness, and correlates with a poor prognosis. Mol Cancer 11: 916-922, 2011.

118. Qi X, Zhang DH, Wu N, Xiao JH, Wang X and Ma W: ceRNA in cancer: Possible functions and clinical implications. J Med Genet 52: 710-718, 2015.

119. Shao T, Wu A, Chen J, Chen H, Lu J, Bai J, Li Y, Xu J and Li X: Identification of module biomarkers from the dysregulated ceRNA-SNIPER network construction network in liver adenocarcinoma. Mol Biosyst 11: 3048-3058, 2015.

120. Xu J, Li Y, Lu J, Pan T, Ding N, Wang Z, Shao T, Zhang J, Wang L and Li X: The mRNA related ceRNA-ccRNA landscape and significance across 20 major cancer types. Nucleic Acids Res 43: 8169-8182, 2015.

121. Feng T, Shao F, Wu Q, Zhang X, Xu D, Qian K, Xie Y, Wang S, Xu N, Wang D, et al: miR-124 downregulation leads to breast cancer progression via LncRNA-MALAT1 regulation and CDK4/ERF2 signaling activation. Oncotarget 7: 16205-16216, 2016.

122. Jin H, Li Q, Cao F, Wang S, Wang RT, Wang Y, Tan QY, Li CR, Zou H, Wang D, et al: miR-124 Inhibits Lung Tumorigenesis Induced by K-ras Mutation and NKNK. Mol Ther Nucleic Acids 9: 145-154, 2017.

123. Wang M, Meng B, Liu Y, Yu J, Chen Q and Liu Y: miR-124 Inhibits Growth and Enhances Radiation-Induced Apoptosis in Non-Small Cell Lung Cancer by Inhibiting STAT3. Cell Physiol Biochem 44: 2017-2028, 2017.

124. Zhang X, Gao F, Zhou H, Wang H, Shi G and Tan D: UCA1 regulates the Growth and Metastasis of Pancreatic Cancer by inhibiting EGF and TGF-β receptors in the pancreas. Pharmacol Toxicol 91: 321-326, 2002.

125. Clerc P, Saillan-Barreau C, Desbois C, Pradayrol L, Fourmy D and Roche A: Combined effects of PI3K and SRC kinase inhibitors with administration of antimicrobial peptides, by targeting CXCR4-p21 signaling. Int J Mol Sci 19: 19, 2018.

126. Hua R, Han S, Zhang N, Dai Q, Liu T and Li J: cPKC enhances pancreatic cancer cell invasion by suppressing the PI3K/Akt pathway. Mol Med Rep 16: 4113-4118, 2017.

127. Wei J, Kuang W, Wu B, Xie C, Liu C and Tu Z: IL-12 induces autophagy in human breast cancer cells through AMPK and the PI3K/Akt pathway. Mol Med Rep 16: 4113-4118, 2017.

128. Wang L, Zhang Q, Mo W, Feng J, Li S, Li J, Liu T, Xu S, Wang W, Lu X, et al: Quercetin prevents hepatic fibrosis by inhibiting hepatic stellate cell activation and reducing autophagy via the TGF-β/Smad3 and PI3K/Akt pathways. Sci Rep 7: 9289, 2017.

129. Ren L, Han W, Yang H, Sun F, Xu S, Hu S, Zhang M, He X, Hua J and Peng S: Autophagy stimulated proliferation of porcine PSCs might be regulated by the canonical Wnt signaling pathway. Biochem Biophys Res Commun 479: 537-543, 2016.

130. Liu R, Feng J, Dong S and Ding Z: Regulation of autophagy of prostate cancer cells by β-catenin signaling. Cell Physiol Biochem 35: 926-932, 2015.

131. Zhao S, Li L, Wang S, Yu C, Xiao B, Lin L, Cong W, Cheng J, Yang W, Sun W, et al: H2O2 treatment or serum deprivation induces autophagy and apoptosis in naked-mole-rat skin fibroblasts by inhibiting the PI3K/Akt signaling pathway. Oncotarget 7: 8439-84850, 2016.

132. Lu X, Lv S, Mi Y, Wang L and Wang G: Neuroprotective effect of miR-665 against sevoflurane anesthesia-induced cognitive dysfunction in rats through PI3K/Akt signaling pathway by targeting insulin-like growth factor 2. Am J Transl Res 9: 1344-1356, 2017.

133. Su N, Wang P and Li Y: Role of Wnt/β-catenin pathway in inducing autophagy and apoptosis in multiple myeloma cells. Oncol Lett 12: 4623-4629, 2016.

134. Kai Y, Qiang C, Xinixin P, Miaomiao Z and Kuialu L: Decreased miR-154 expression and its clinical significance in human colorectal cancer. World J Surg Oncol 13: 195, 2015.

135. Xu H, Fei D, Zong S and Fan Z: MicroRNA-154 inhibits growth and invasion of breast cancer cells through targeting E2F5. Am J Transl Res 8: 1170-1178, 2016.

136. Liu ZQ, Zhao S and Fu WQ: Insulin-like growth factor I receptor-mediated cell survival in hypoxia depends on the promotion of autophagy via suppression of the PI3K/Akt/mTOR signaling pathway. Mol Med Rep 15: 2136-2142, 2017.

137. Ceperuelo-Mallafre V, Ejarque M, Ceperuelo-Mallafré V, Duran X, Krell D, Castellano L, Colombo T, Giovannetti E, Krell J, et al: Combined effects of PI3K and SRC kinase inhibitors with administration of antimicrobial peptides, by targeting CXCR4-p21 signaling. Int J Mol Sci 19: 19, 2018.

138. Shrivaram S, Crist KA, Chaudhuri B, Mucci SJ and Chaudhuri PK: Effect of CCK receptor antagonist on growth of pancreatic adenocarcinoma. J Surg Res 53: 234-237, 1992.

139. Clarindo P, Desbois C, Pradayrol L, Foucart M and Dufresne M: Transgenic mice expressing cholecystokinin 2 receptors in the pancreas. Pharmacol Toxicol 91: 321-326, 2002.
153. Shang C, Zhu W, Liu T, Wang W, Huang G, Huang J, Zhao P, Zhao Y and Yao S: Characterization of long non-coding RNA expression profiles in lymph node metastasis of early-stage cervical cancer. Oncol Rep 35: 3185-3197, 2016.

154. Broniezki AW, Schuster M and Schmitz I: Autophagy in T-cell development, activation and differentiation. Immunol Cell Biol 93: 25-34, 2015.

155. Martinez-Lopez N, Athonvarangkul D and Singh R: Autophagy and aging. Adv Exp Med Biol 847: 73-87, 2015.

156. Tan Y, Gong Y, Dong M, Pei Z and Ren J: Role of autophagy in inherited metabolic and endocrine myopathies. Biochim Biophys Acta Mol Basis Dis 1865: 48-55, 2018.

157. Chu CT: Autophagy in Neurological Diseases: An update. Neurobiol Dis S0969-9961(18)30728-9, 2018.

158. Yang A, Rajeshkumar NV, Wang X, Yabuuchi S, Alexander BM, Chu GC, Von Hoff DD, Maitra A and Kimmelman AC: Autophagy is critical for pancreatic tumor growth and progression in tumors with p53 alterations. Cancer Discov 4: 905-913, 2014.

159. Zhan Y, Wang K, Li Q, Zou Y, Chen B, Gong Q, Ho HI, Yin T, Zhang F, Lu Y, et al: The Novel Autophagy Inhibitor Alpha-Hederin Promoted Paclitaxel Cytotoxicity by Increasing Reactive Oxygen Species Accumulation in Non-Small Cell Lung Cancer Cells. Int J Mol Sci 19: 19, 2018.

160. Chen S, Wu J, Jiao K, Wu Q, Ma J, Chen D, Kang J, Zhao G, Shi Y, Fan D, et al: MicroRNA-495-3p inhibits multidrug resistance by modulating autophagy through GRP78/mTOR axis in gastric cancer. Cell Death Dis 9: 1070, 2018.

161. Verma SP and Das P: Monensin induces cell death by autophagy and inhibits matrix metalloproteinase 7 (MMP7) in UOK146 renal cell carcinoma cell line. In Vitro Cell Dev Biol Anim 54: 736-742, 2018.